Early uncertainty about the safety of noninterferon antivirals in patients with liver cancer may have contributed to the slow acceptance of direct-acting antiviral agents in this population.
The annual cost of alcohol-related liver disease in the United States is projected to more than double, from $31 billion in 2022 to $66 billion in 2040, a new analysis has found.
Patients with alcohol-related liver disease, including those who have high-risk portal hypertension, can benefit from alcohol abstinence, suggests a study that also underlines a need for patient counseling.